MCID: PDT001
MIFTS: 41

Pediatric Lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Pediatric Lymphoma

MalaCards integrated aliases for Pediatric Lymphoma:

Name: Pediatric Lymphoma 12 15
Childhood Lymphoma 73

Classifications:



External Ids:

Disease Ontology 12 DOID:5823
NCIt 50 C5165
UMLS 73 C1332979

Summaries for Pediatric Lymphoma

MalaCards based summary : Pediatric Lymphoma, also known as childhood lymphoma, is related to hemangioma of spleen and lymphoma. An important gene associated with Pediatric Lymphoma is DAPK1 (Death Associated Protein Kinase 1), and among its related pathways/superpathways are NF-kappaB Signaling and Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell. The drugs Etoposide and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and t cells, and related phenotypes are Synthetic lethal with vaccinia virus (VACV) infection and cellular

Related Diseases for Pediatric Lymphoma

Diseases related to Pediatric Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 77)
# Related Disease Score Top Affiliating Genes
1 hemangioma of spleen 10.3 CD9 SMUG1
2 lymphoma 10.3
3 gallbladder small cell carcinoma 10.3 NCAM1 SMUG1
4 bone lymphoma 10.3 CD22 SMUG1
5 breast lymphoma 10.3 CD79A SMUG1
6 selective igg deficiency disease 10.2 CD79A NCAM1
7 renal adenoma 10.2 B3GAT1 NCAM1
8 viral esophagitis 10.2 B3GAT1 CD79A
9 epithelial predominant wilms' tumor 10.2 B3GAT1 NCAM1
10 jejunal adenocarcinoma 10.2 MSH6 SMUG1
11 lung combined type small cell carcinoma 10.2 MME NCAM1
12 extrahepatic bile duct adenocarcinoma 10.2 MME NCAM1
13 mediastinal cancer 10.2 CD79A NCAM1 SMUG1
14 parasitic ichthyosporea infectious disease 10.2 NCAM1 RHOJ
15 rhinosporidiosis 10.2 NCAM1 RHOJ
16 lymphosarcoma 10.2 CD22 CD79A SMUG1
17 natural killer cell leukemia 10.2 B3GAT1 NCAM1
18 viral infectious disease 10.2 CD81 IRF3 IRF7
19 spleen angiosarcoma 10.1 CD34 SMUG1
20 tibial adamantinoma 10.1 CD34 SMUG1
21 breast leiomyosarcoma 10.1 CD34 SMUG1
22 bone epithelioid hemangioma 10.1 CD34 SMUG1
23 testicular leukemia 10.1 CD79A CD9
24 lung meningioma 10.1 CD34 NCAM1
25 orbital plasma cell granuloma 10.1 MME NCAM1
26 bladder lymphoma 10.1 CD79A MME
27 malignant epithelioid hemangioendothelioma 10.1 CD34 SMUG1
28 gastric small cell carcinoma 10.1 B3GAT1 NCAM1
29 lymphoma, mucosa-associated lymphoid type 10.1 CD79A MME SMUG1
30 small intestine lymphoma 10.1 CD22 CD79A MSH6
31 granulomatous myositis 10.1 NCAM1 SMUG1 TNFRSF8
32 mature b-cell neoplasm 10.1 CD79A MME NCAM1
33 intravascular fasciitis 10.1 ALK CD34
34 plexiform schwannoma 10.1 B3GAT1 CD34
35 mediastinal malignant lymphoma 10.1 CD79A DAPK1 TNFRSF8
36 breast myofibroblastoma 10.1 CD34 MME
37 eccrine adenocarcinoma 10.1 CD34 SMUG1
38 conventional angiosarcoma 10.1 CD34 NCAM1
39 malignant leydig cell tumor 10.1 MME TNFRSF8
40 venous hemangioma 10.1 CD34 KLF4
41 breast angiosarcoma 10.1 CD34 SMUG1
42 adult lymphoma 10.1 ALK SMUG1 TNFRSF8
43 invasive malignant thymoma 10.1 CD34 MME
44 psammomatous meningioma 10.1 CD34 MME
45 t-cell/histiocyte rich large b cell lymphoma 10.1 MME TNFRSF8
46 internal hemorrhoid 10.0 ALK CD34
47 chronic orbital inflammation 10.0 MME NCAM1
48 ovarian solid teratoma 10.0 CD34 TNFRSF8
49 solitary osseous plasmacytoma 10.0 CD79A NCAM1
50 meningioma, familial 10.0 CD34 KLF4 SMUG1

Graphical network of the top 20 diseases related to Pediatric Lymphoma:



Diseases related to Pediatric Lymphoma

Symptoms & Phenotypes for Pediatric Lymphoma

GenomeRNAi Phenotypes related to Pediatric Lymphoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with vaccinia virus (VACV) infection GR00362-A 9.02 CD79A CD9 MME MSH6 NCAM1

MGI Mouse Phenotypes related to Pediatric Lymphoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.02 CD22 CD34 CD79A CD9 DAPK1 IRF3
2 hematopoietic system MP:0005397 10 CD22 CD34 CD79A CD81 CD9 DAP
3 homeostasis/metabolism MP:0005376 10 ALK CD34 CD79A CD81 DAP DAPK1
4 immune system MP:0005387 9.77 CD22 CD34 CD79A CD81 CD9 DAP
5 neoplasm MP:0002006 9.17 ALK CD34 CD79A KLF4 MSH6 RHOJ

Drugs & Therapeutics for Pediatric Lymphoma

Drugs for Pediatric Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 71)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etoposide Approved Phase 2, Phase 3,Phase 1 33419-42-0 36462
2
Lenograstim Approved, Investigational Phase 2, Phase 3 135968-09-1
3
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 6055-19-2, 50-18-0 2907
4
rituximab Approved Phase 2, Phase 3 174722-31-7 10201696
5
Prednisone Approved, Vet_approved Phase 2, Phase 3 53-03-2 5865
6
Methotrexate Approved Phase 2, Phase 3,Phase 1 59-05-2, 1959-05-2 126941
7
Vincristine Approved, Investigational Phase 2, Phase 3 57-22-7, 2068-78-2 5978
8
leucovorin Approved Phase 2, Phase 3,Phase 3,Phase 1 58-05-9 6006 143
9
Rasburicase Approved, Investigational Phase 2, Phase 3 134774-45-1
10
Doxorubicin Approved, Investigational Phase 2, Phase 3,Phase 1 23214-92-8 31703
11
Levoleucovorin Approved, Investigational Phase 2, Phase 3 68538-85-2
12
Cytarabine Approved, Investigational Phase 2, Phase 3 147-94-4 6253
13
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 1 59-30-3 6037
14
Doxil Approved June 1999 Phase 2, Phase 3,Phase 1 31703
15 Hormones Phase 2, Phase 3,Phase 1
16 Antineoplastic Agents, Hormonal Phase 2, Phase 3,Phase 1
17 Hormone Antagonists Phase 2, Phase 3,Phase 1
18 Alkylating Agents Phase 2, Phase 3,Phase 1
19 Anti-Inflammatory Agents Phase 2, Phase 3,Phase 1
20 Antineoplastic Agents, Alkylating Phase 2, Phase 3,Phase 1
21 Etoposide phosphate Phase 2, Phase 3,Phase 1
22 Antimetabolites Phase 2, Phase 3,Phase 1,Early Phase 1
23 glucocorticoids Phase 2, Phase 3,Phase 1
24 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3,Phase 1
25 Topoisomerase Inhibitors Phase 2, Phase 3,Phase 1
26 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1,Early Phase 1
27 Adjuvants, Immunologic Phase 2, Phase 3
28 Trace Elements Phase 2, Phase 3
29 Immunologic Factors Phase 2, Phase 3,Phase 1
30 Vitamins Phase 2, Phase 3
31 Vitamin B9 Phase 2, Phase 3,Phase 1
32 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
33 Antiviral Agents Phase 2, Phase 3
34 Hematinics Phase 2, Phase 3
35 Folate Phase 2, Phase 3,Phase 1
36 Anti-Bacterial Agents Phase 2, Phase 3,Phase 1
37 Antirheumatic Agents Phase 2, Phase 3,Phase 1
38 Antibiotics, Antitubercular Phase 2, Phase 3,Phase 1
39 Protective Agents Phase 2, Phase 3
40 Vitamin B Complex Phase 2, Phase 3,Phase 1
41 Antidotes Phase 2, Phase 3
42 Anti-Infective Agents Phase 2, Phase 3
43 Micronutrients Phase 2, Phase 3
44
Vinblastine Approved Phase 1, Phase 2,Phase 2 865-21-4 241903 13342
45
Dacarbazine Approved, Investigational Phase 1, Phase 2 4342-03-4 5351166
46
Capecitabine Approved, Investigational Phase 1, Phase 2 154361-50-9 60953
47
Nivolumab Approved Phase 1, Phase 2 946414-94-4
48
Genistein Investigational Phase 2 446-72-0 5280961
49 Antineoplastic Agents, Phytogenic Phase 1, Phase 2,Phase 2
50 Antimitotic Agents Phase 1, Phase 2,Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Mature B-Cell Lymphoma And Leukemia Study III Recruiting NCT01046825 Phase 2, Phase 3 COPAD;COP, COPD M3, CYM;COP, COPADM8, CYVE
2 A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma Recruiting NCT02979522 Phase 1, Phase 2 Brentuximab vedotin;Doxorubicin;Vinblastine;Dacarbazine
3 Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) Recruiting NCT02624388 Phase 2 Genistein;Placebo
4 Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors or Lymphoma Not yet recruiting NCT03585465 Phase 1, Phase 2 Vinblastine;Cyclophosphamide;Capecitabine;Nivolumab
5 Study of 6-Thioguanine in Combination With 6-Mercaptopurine During Maintenance Therapy of Childhood Lymphoma Withdrawn NCT02141100 Phase 1, Phase 2 6-thioguanine
6 Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies Completed NCT01900509 Phase 1 Bendamustine;Clofarabine;Etoposide;Etoposide phosphate;Dexamethasone
7 Dose Escalation Study of CLR 131 in Children and Adolescents With Relapsed or Refractory Malignant Brain Cancer, Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma Not yet recruiting NCT03478462 Phase 1 CLR 131
8 Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults Recruiting NCT03445858 Early Phase 1 Pembrolizumab;Decitabine
9 Prospective Cohort Study Depending on the Use of Palliative Care for Advanced Stage of Cancer Patients Active, not recruiting NCT03222258
10 Proton Radiation for Lymphoma Involving Mediastinum Terminated NCT01751412 Not Applicable

Search NIH Clinical Center for Pediatric Lymphoma

Genetic Tests for Pediatric Lymphoma

Anatomical Context for Pediatric Lymphoma

MalaCards organs/tissues related to Pediatric Lymphoma:

41
B Cells, Bone, T Cells, Lung, Colon, Spleen, Small Intestine

Publications for Pediatric Lymphoma

Articles related to Pediatric Lymphoma:

(show top 50) (show all 87)
# Title Authors Year
1
Pharmacotherapeutic Management of Pediatric Lymphoma. ( 29127674 )
2018
2
Predictive Value of FDG PET/CT Versus Bone Marrow Biopsy in Pediatric Lymphoma. ( 30358625 )
2018
3
A strong spatial association between e-waste burn sites and childhood lymphoma in the West Bank, Palestine. ( 30259977 )
2018
4
Late-onset cardiomyopathy among survivors of childhood lymphoma treated with anthracyclines: a systematic review. ( 30273645 )
2018
5
Translation, psychometric validation, and baseline results of the Patient-Reported Outcomes Measurement Information System (PROMIS) pediatric measures to assess health-related quality of life of patients with pediatric lymphoma in Malawi. ( 30015407 )
2018
6
Pediatric Lymphoma. ( 28864732 )
2017
7
Erratum to: Role of PET/CT in malignant pediatric lymphoma. ( 28058463 )
2017
8
Evaluation of maternal and perinatal characteristics on childhood lymphoma risk: A population-based case-control study. ( 27896915 )
2017
9
Experiences with late effects-related care and preferences for long-term follow-up care among adult survivors of childhood lymphoma. ( 28236146 )
2017
10
Adverse Health Outcomes and Associations with Self-Reported General Health in Childhood Lymphoma Survivors. ( 28837384 )
2017
11
A Pilot Study of 18F-FLT PET/CT in Pediatric Lymphoma. ( 27313888 )
2016
12
Assessment of Sequential PET/MRI in Comparison With PET/CT of Pediatric Lymphoma: A Prospective Study. ( 26901021 )
2016
13
Comparison of 11C-methionine and 18F-FDG PET-CT for staging and follow-up of pediatric lymphoma. ( 27609791 )
2016
14
Socioeconomic Factors Impact Inpatient Mortality in Pediatric Lymphoma Patients. ( 27433403 )
2016
15
Evaluation of diagnostic performance of whole-body simultaneous PET/MRI in pediatric lymphoma. ( 27003132 )
2016
16
Imaging of primary pediatric lymphoma of bone. ( 27043729 )
2016
17
Emerging immunotherapy in pediatric lymphoma. ( 26616565 )
2016
18
Right ventricular function in long-term adult survivors of childhood lymphoma and acute lymphoblastic leukaemia. ( 26917232 )
2016
19
Utility of Global Longitudinal Strain by Echocardiography to Detect Left Ventricular Dysfunction in Long-Term Adult Survivors of Childhood Lymphoma and Acute Lymphoblastic Leukemia. ( 27296561 )
2016
20
Treatment of pediatric lymphoma in Japan: Current status and plans for the future. ( 26096060 )
2015
21
Childhood lymphoma incidence patterns by ICCC-3 subtype in Mexico City metropolitan area population insured by Instituto Mexicano del Seguro Social, 1996-2010. ( 25779380 )
2015
22
Residential Radon Exposure and Incidence of Childhood Lymphoma in Texas, 1995-2011. ( 26404336 )
2015
23
Dose-Effect Relationship of Alkylating Agents on Testicular Function in Male Survivors of Childhood Lymphoma. ( 26561347 )
2015
24
Left ventricular function in long-term survivors of childhood lymphoma. ( 24948492 )
2014
25
Pediatric lymphoma diagnosis: role of FNAC, biopsy, immunohistochemistry and molecular diagnostics. ( 23925793 )
2013
26
Pediatric lymphoma: metabolic tumor burden as a quantitative index for treatment response evaluation. ( 22033780 )
2012
27
Is birth weight associated with childhood lymphoma? A meta-analysis. ( 21351088 )
2012
28
Gonadal function and parenthood 20 years after treatment for childhood lymphoma: a cross-sectional study. ( 22021108 )
2012
29
Agreement between diagnoses of childhood lymphoma assigned in Uganda and by an international reference laboratory. ( 23277743 )
2012
30
Role of limited whole-body PET/CT in pediatric lymphoma. ( 21512070 )
2011
31
Biopsy versus FDG PET/CT in the initial evaluation of bone marrow involvement in pediatric lymphoma patients. ( 21505896 )
2011
32
Maternal smoking during pregnancy and childhood lymphoma: a meta-analysis. ( 21225624 )
2011
33
Cardiac function in long-term survivors of childhood lymphoma. ( 21318103 )
2011
34
Diagnosis and immunophenotype of 188 pediatric lymphoblastic lymphomas treated within a randomized prospective trial: experiences and preliminary recommendations from the European childhood lymphoma pathology panel. ( 21451365 )
2011
35
Intussusception incidentally detected by FDG-PET/CT in a pediatric lymphoma patient. ( 20449693 )
2010
36
Role of PET/CT in malignant pediatric lymphoma. ( 19756591 )
2010
37
Pediatric lymphoma: a 10-year experience at a tertiary care hospital in Pakistan. ( 20051771 )
2010
38
Methodological issues in the evaluation of FDG PET/CT accuracy in pediatric lymphoma. ( 20821007 )
2010
39
Flowcytometric immunophenotyping in the diagnosis of pediatric lymphoma: how reliable is it and how can we optimize its use? ( 20224437 )
2010
40
Trends in incidence of childhood lymphoma in Khon Kaen, Thailand, 1985-2008. ( 21338216 )
2010
41
Compound heterozygosity for MSH6 mutations in a pediatric lymphoma patient. ( 19194194 )
2009
42
FDG PET and PET/CT in the Management of Pediatric Lymphoma Patients. ( 27156825 )
2008
43
Stem cell transplantation for pediatric lymphoma: past, present and future. ( 18084337 )
2008
44
"It is very hard": treatment for childhood lymphoma from the parents' perspective. ( 18300061 )
2008
45
Expression of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in tissues with a diagnosis of childhood lymphoma. ( 18850474 )
2008
46
The accuracy of PET(CT) in evaluating pediatric lymphoma. ( 17805051 )
2007
47
Comparison of (18)F Flurodeoxyglucose PET with Ga-67 scintigraphy and conventional imaging modalities in pediatric lymphoma. ( 17454627 )
2007
48
Association of Helicobacter pylori and childhood lymphoma. ( 17483706 )
2007
49
Childhood lymphoma and leukaemia. ( 16711332 )
2006
50
(18)F-Fluorodeoxyglucose PET/CT in Childhood Lymphoma. ( 27157365 )
2006

Variations for Pediatric Lymphoma

Expression for Pediatric Lymphoma

Search GEO for disease gene expression data for Pediatric Lymphoma.

Pathways for Pediatric Lymphoma

GO Terms for Pediatric Lymphoma

Cellular components related to Pediatric Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.92 CD34 CD79A CD9 NCAM1

Biological processes related to Pediatric Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of immune response GO:0050776 9.56 CD22 CD34 CD81 IRF7
2 viral process GO:0016032 9.55 CD81 IRF3 IRF7 MSH6 NCAM1
3 interferon-gamma-mediated signaling pathway GO:0060333 9.5 IRF3 IRF7 NCAM1
4 cellular response to low-density lipoprotein particle stimulus GO:0071404 9.46 CD81 CD9
5 positive regulation of interferon-alpha production GO:0032727 9.43 IRF3 IRF7
6 regulation of type I interferon production GO:0032479 9.4 IRF3 IRF7
7 positive regulation of type I interferon-mediated signaling pathway GO:0060340 9.37 IRF3 IRF7
8 MDA-5 signaling pathway GO:0039530 8.96 IRF3 IRF7
9 type I interferon biosynthetic process GO:0045351 8.62 IRF3 IRF7

Sources for Pediatric Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....